Dr Joanna Achinger-Kawecka

Senior Research Officer - Epigenetics Research

Dr Joanna Achinger-Kawecka

Dr Joanna Achinger-Kawecka’s research focuses on investigating the role of the 3D epigenome in cancer, particularly in driving tumour progression and treatment resistance in breast and prostate cancer. Joanna completed her PhD at the University of Tuebingen, Germany, investigating microRNA signature

Biography

Dr Joanna Achinger-Kawecka’s research focuses on investigating the role of the 3D epigenome in cancer, particularly in driving tumour progression and treatment resistance in breast and prostate cancer. Joanna completed her PhD at the University of Tuebingen, Germany, investigating microRNA signatures as predictive biomarkers for breast cancer treatment outcome.

Following her PhD, Joanna joined the laboratory of Prof Susan Clark at the Garvan Institute, where she established cutting-edge experimental and computational approaches to study the 3D genome organization during development and progression of cancer.

Dr Joanna Achinger-Kawecka’s research focuses on investigating the role of the 3D epigenome in cancer, particularly in driving tumour progression and treatment resistance in breast and prostate cancer. Joanna completed her PhD at the University of Tuebingen, Germany, investigating microRNA signatures as predictive biomarkers for breast cancer treatment outcome.

Following her PhD, Joanna joined the laboratory of Prof Susan Clark at the Garvan Institute, where she established cutting-edge experimental and computational approaches to study the 3D genome organization during development and progression of cancer.

Awards and Honours

2021 - NBCF Fellowship (2021 - 2024)
2020 - Cancer Council NSW Project Grant (2020 - 2022)
2020 - UNSW Cellular Genomics Futures Institute Seed Grant (2020 - 2021)
2019 - Estee Lauder Companies’ Breast Cancer Campaign Award
2019 - EMBO Travel Award
2018 - CASS Foundation Travel Grant
2017 - The Ian Potter Foundation Travel Grant
2016 - Best Postdoc Poster Prize, 24th St Vincent’s Campus Research Symposium
2016 - Heliflite Young Explorer Award
2015 - Best Oral Presentation Prize, 23rd St Vincent’s Campus Research Symposium
2011 – FP7 Marie Curie Initial Training Network “Fighting Drug Failure” Fellowship

Education

2014 – PhD (Pharmaceutical Sciences), Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology and University Tuebingen - Germany
2011 – MSc (Biotechnology), Warsaw University of Life Sciences - Poland

Fundings

National Breast Cancer Foundation Investigator Initiated Research Scheme Grant and Mavis Robertson Fellowship (2021 - 2024)

Cancer Council NSW Project Grant (2020 - 2022)

UNSW Cellular Genomics Futures Institute Seed Grant (2020 - 2021)

Selected Publications

Du Q, et al., Achinger-Kawecka, J and Clark SJ. (2021) DNA methylation is required for DNA replication timing precision and 3D genome integrity. Cell Reports 36 (12), 109722

Achinger-Kawecka, J., Valdes-Mora, F., Luu, P. et al. (2020) Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer. Nature Commun 11, 320 doi:10.1038/s41467-019-14098-x

Khoury, A., Achinger-Kawecka, J., Bert, S.A. et al. (2020) Constitutively bound CTCF sites maintain 3D chromatin architecture and long-range epigenetically regulated domains. Nature Commun 11, 54 https://doi.org/10.1038/s41467-019-13753-7

Achinger-Kawecka J, Taberlay PC, Clark SJ. (2017) Alterations in Three-Dimensional Organization of the Cancer Genome and Epigenome. Cold Spring Harb Symp Quant Biol. doi: 10.1101/sqb.2016.81.031013.

Achinger-Kawecka J, Clark SJ. (2017) Disruption of the 3D cancer genome blueprint. Epigenomics, 9 (1): 47-55 doi:10.2217/epi-2016-0111

Taberlay PC*, Achinger-Kawecka J*, et al. (2016) Three-dimensional disorganisation of the cancer genome occurs coincident with long range genetic and epigenetic alterations. Genome Research. 26: 719-731 *Equal first authors

Reiner Hoppe*, Joanna Achinger-Kawecka*, et al. (2014) Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment. European Journal of Cancer doi:10.1016/j.ejca.2013.07.145 *Equal first authors